74 results
425
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
within the six (6) years prior to the date hereof been the subject of an examination, investigation or audit by a Governmental Authority or the subject … there been any written complaint, audit, proceeding, investigation or claim against the Company or any Subsidiary initiated by (i) any Person, (ii) any
425
EX-10.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
an action, claim, suit, investigation or proceeding (including, without limitation, an informal investigation or partial proceeding, such as a deposition … , proceeding or investigation pending against or affecting the Company, any Subsidiary or any of their respective properties before or by any court
425
EX-10.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Business combination disclosure
8:33am
or several (collectively, “Claims”), incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation … of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Remaining Registrable Securities
8-K
EX-2.1
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
within the six (6) years prior to the date hereof been the subject of an examination, investigation or audit by a Governmental Authority or the subject … there been any written complaint, audit, proceeding, investigation or claim against the Company or any Subsidiary initiated by (i) any Person, (ii) any
8-K
EX-10.2
HEPA
Hepion Pharmaceuticals, Inc.
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
or several (collectively, “Claims”), incurred in investigating, preparing or defending any action, claim, suit, inquiry, proceeding, investigation … of any investigation made by or on behalf of the Indemnified Person and shall survive the transfer of the Remaining Registrable Securities
8-K
EX-10.1
0wm3ilef0kvxl2 geh9w
22 Jul 24
Entry into a Material Definitive Agreement
8:28am
8-K
EX-10.1
mfnvh jfpmv9
2 Oct 23
Hepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq Rules
6:29pm
8-K
EX-1.1
098fy7c6ylhy5d mj
21 Jul 23
Entry into a Material Definitive Agreement
4:41pm
S-8
EX-5.1
ri04u0
14 Jul 23
Registration of securities for employees
5:12pm
8-K
EX-10.2
ru8kk7zt6zvg0 pcyal1
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-10.1
fxrm y1sex
8 Nov 22
Hepion Pharmaceuticals Announces Pricing of $20.0 Million Private Placement of Convertible Redeemable Preferred Stock
8:41pm
8-K
EX-1.1
xjp1z5ixl ah3jq3cv
17 Feb 21
Hepion Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
8:06am
S-8
EX-5.1
dtia r86db8jxq
19 Jan 21
Registration of securities for employees
12:00am
8-K
EX-1.1
fn2ir
27 Nov 20
Hepion Pharmaceuticals Prices Public Offering
1:48pm